Patent classifications
A61K9/0017
Device in the Form of a Cannabinoid-Based Polymer Matrix
The invention relates to a device for topical application in the form of a polymer matrix containing at least one active ingredient from the family of cannabinoids, alone or as a mixture with other active ingredients. The invention preferably relates to the device in the form of a collar, to the use thereof for improving the well-being and the mobility of an animal to which the device is applied, and to a process for producing the device.
Method of Disease Control
A method of treating a subject having a disease caused by a pathogen, preferably an acid-labile pathogen, said method comprising the step of applying to the subject a therapeutically effect amount of a topical composition having biocidal properties or both pain-relieving and biocidal properties. The composition can be used to treat or control bacterial, viral, fungal or infestational pathogens, and related diseases. The disease can be foot and mouth disease (FMD) or scabby mouth (orf), caused by an acid-labile virus. The topical composition can be used to treat hoof rot/footrot/foot abscess and viral lesions.
LONG-ACTING SPIRO-ISOXAZOLINE ANTIPARASITIC COMPOSITIONS
The invention describes a long-acting composition comprising a spiro-azetidine isoxazoline of Formula (1) or (2)
##STR00001##
wherein R.sup.1a, R.sup.1b, R.sup.1c and R.sup.2 are as described herein, and stereoisomers thereof. The composition is a veterinary composition and also comprises a glycol ether and at least one veterinarily acceptable solvent, and optionally, at least one precipitation inhibitor, antioxidant and additional veterinary agent, and any mixture thereof. The invention also includes a method of treating an animal with a parasitic infestation by administering the long-acting composition to the animal in need thereof.
PARASITICIDAL COLLAR COMPRISING ISOXAZOLINE COMPOUNDS
Provided herein are long-acting antiparasitic devices comprising parasiticidal isoxazoline active agent for external use on an animal to treat and/or prevent parasitic infestations by ectoparasites, and in some embodiments, also parasitic infections. The disclosure also describes methods and uses of the antiparasitic external devices to treat and/or prevent parasitic infestations and/or infections in an animal.
METHOD OF TREATING BOVINE MASTITIS
A method of treating or preventing mastitis in a bovine animal comprising administering to the animal a therapeutically effective amount of particular microbes thereby treating or preventing mastitis in the animal.
<i>Lactococcus garvieae </i>bacteriophage Lac-GAP-3 and use thereof in inhibiting proliferation of <i>Lactococcus garvieae </i>bacteria
The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.
Antimicrobial composition
The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.
PARASITICIDAL FORMULATIONS AND USE THEREOF
A formulation for the dermal control of endoparasites comprising a macrocyclic lactone and method of use thereof.
Transdermal solvent system and methods of use
Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.
Active ingredient obtained from <i>Ophiopogon japonicus </i>for the treatment of atopic dermatitis
Methods of treatment for atopic dermatitis in a human subject or animal, the methods comprising administering topically to the human subject or animal an active ingredient obtained from Ophiopogon japonicus.